{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1"},{"groupId":"OG001","value":"92.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"263"},{"groupId":"OG001","value":"286"}],"units":"Participants"}],"description":"Percentage of participants with at least one adverse event.","groups":[{"description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"},{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"Safety analyses included treated participants, defined as randomized participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to until data cut-off on 8 March 2022 (up to approximately 79.5 months)","title":"Percentage of Participants With at Least One Adverse Event","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}